

March 4, 2024

Raymond James 45th Annual Institutional Investors Conference



Myriad
genetics®

©2024 Myriad Genetics, Inc.

Forward-looking statements and Non-GAAP financial measures

Some of the information presented here today contains projections or other forward-looking statements regarding future events or the future financial performance of the Company.

FORWARD-LOOKING STATEMENTS AND DISCLAIMERS

These statements are based on management's current expectations and the actual events or results may differ materially and adversely from these expectations. We refer you to the documents the Company files from time to time with the Securities and Exchange Commission, specifically, the Company's annual report on Form 10-K, its quarterly reports on Form 10-Q, and its current reports on Form 8-K. These documents identify important risk factors that could cause the actual results to differ materially from those contained in the Company's projections or forward-looking statements. All third-party marks—® and ™—are the property of their respective owners. Certain market and industry data has been obtained from third-party sources, which the Company believes are reliable, but the Company has not independently verified the information provided by third-party sources. Unless otherwise noted, market growth rates used in this presentation are estimates based on Company and third-party industry research.

NON-GAAP FINANCIAL MEASURES

In this presentation, the Company's financial results and financial guidance are provided in accordance with accounting principles generally accepted in the United States (GAAP) and using certain non-GAAP financial measures. Management believes that presentation of operating results using non-GAAP financial measures provides useful supplemental information to investors and facilitates the analysis of the Company's core operating results and comparison of operating results across reporting periods. Management also uses non-GAAP financial measures to establish budgets and to manage the Company's business. Definitions of the non-GAAP financial measures and a reconciliation of the GAAP to non-GAAP financial results are provided in the Appendix to this presentation.

The Company does not provide forward-looking guidance on a GAAP basis as the company is unable to provide a quantitative reconciliation of forward-looking non-GAAP measures to the most directly comparable forward-looking GAAP measure, without unreasonable effort, because of the inherent difficulty in accurately forecasting the occurrence and financial impact of the various adjusting items necessary for such reconciliations that have not yet occurred, are dependent on various factors, are out of the company's control, or cannot be reasonably predicted. Such adjustments include, but are not limited to, real estate optimization and transformation initiatives, certain litigation charges and loss contingencies, costs related to acquisitions/divestitures and the related amortization, impairment and related charges, and other adjustments. For example, stock-based compensation may fluctuate based on the timing of employee stock transactions and unpredictable fluctuations in the company's stock price. Any associated estimate of these items and its impact on GAAP performance could vary materially.




Revealing the power of genetic science – for everyone

Mission

We advance health and well-being for all, empowering every individual by revealing the answers inside each of us.

Vision

As a leader in genetic testing and precision medicine, we provide insights that help people take control of their health and enable healthcare providers to better detect, treat and prevent disease.



Moving from transformation to innovation and growth

Myriad Genetics at-a-glance



A leader in genetic testing

Established franchises in hereditary cancer, pharmacogenomics, and prenatal testing



30+ years of scientific and commercial achievements

1,000+ scientific publications and counting



45,000+
active ordering
healthcare providers¹

70
net promoter score²

~2,700
employees²



10%+ revenue growth year-over-year for fifth consecutive quarter³

Commercial execution driving volume growth; price stability



Market-leading gross margins; healthy balance sheet



Innovation in '24 and beyond

Expect to launch multiple differentiated tests in prenatal and oncology

Myriad[®]
genetics

1. As of December 31, 2023

2. As of 4th quarter, 2023

3. As of December 2023 and excludes contribution from change of revenue estimates

Serving a more patient-centric healthcare system: Myriad Genetics' overarching goals



Innovating in precision medicine to detect disease, support treatment decisions and improve clinical outcomes

Develop best-in-class test quality and scientific insights

- Industry-leading R&D delivers critical prenatal insights earlier in pregnancy than ever before
- Combined, MyRisk® Hereditary Cancer Test + RiskScore® is a more accurate predictor of cancer risk than Tyrer-Cuzick*
- Breakthrough science and clinical studies address the growing mental health crisis



Ease of use for patients and healthcare providers

Removing friction

- Epic EMR integration enables 600,000+ HCPs to order Myriad tests
- Telemedicine and chatbot platforms to meet patients where they are
- Enhancing portals for better experience in ordering and reporting by providers



Improving access for all and reducing healthcare costs

Serve more patients by broadening adoption and access

- Patient outreach to support underserved populations and ethnicities
- New point-of-care financial accessibility tools and payment programs

Innovation collaboration: Partnering with leading healthcare visionaries



AstraZeneca

Myriad genetics

Lifepoint Health

Volpara HEALTH

DNAnexus®

gsk GlaxoSmithKline

Intermountain Health

SimonMed® Imaging
See Tomorrow Today®

SIRIL
Communication for Health

MSD

UnitedHealthcare®


Clarified PRECISION MEDICINE

illumina

Epic

Cancer IQ

Acquired Intermountain Precision Genomics' laboratory, together with Precise Tumor and Precise Liquid



Precise™ Liquid

Molecular Profile Test

Precise Liquid
Q3 targeted launch at Salt Lake Campus West



3 focus areas: Oncology, Women's Health and Pharmacogenomics

Oncology

Clarifying cancer treatment with genetic and genomic insights and companion diagnostic tests that are designed to work with corresponding drugs and treatments.

Oncologist
Surgeon
Urologist
Genetic Counselor

MyRisk[®]
Hereditary Cancer Test

MyChoice[®] CDx
Myriad HRD Companion Diagnostic Test

Prolaris[®]
Prostate Cancer Prognostic Test

BRCAAnalysis CDx[®]
Germline Companion Diagnostic Test

EndoPredict[®]
Breast Cancer Prognostic Test

Precise[™] Tumor
Molecular Profile Test

2024E Launch expected
Precise[™] Liquid
Molecular Profile Test

2025E Launch expected
Precise[™] MRD
Molecular Residual Disease Monitoring

Women's Health

A leader in health and wellness with differentiated genetic insights for women of all ancestries, assessing cancer risk and offering prenatal solutions.

OB/GYN
Maternal Fetal Medicine
Primary Care
Genetic Counselor

MyRisk[®] with **RiskScore**[®]
for all ancestries
Hereditary Cancer Test

2025E Launch expected
FirstGene[™]
Multiple Prenatal Screen

Foresight[®]
Carrier Screen

Prequel[®]
Prenatal Screen

SneakPeek[®]

Pharmacogenomics

Using genetic insights to help physicians understand how genetic alterations impact patient response to antidepressants and other drugs.

Psychiatrist
Primary Care
Nurse Practitioner/Physician Assistant

GeneSight[®]
Mental Health Medication Test

Diversified portfolio within large, fragmented, actionable markets

	Oncology					Women's Health		PGx
	AFFECTED HCT + GERMLINE	TUMOR PROFILING ³	MRD	HRD ²	UROLOGY	PRENATAL	UNAFFECTED HCT	PGx
Actionable Market Opp. ¹	\$1.2B	\$500M	\$20B+	\$350M	\$600M	\$2.3B	\$3B	\$5B
Market Penetration	~65%	~45%	<5%	~40%	~35%	~50%	<15%	~15%
Myriad Products	MyRisk[®] Hereditary Cancer Test BRACAnalysis CDx[®] Germline Companion Diagnostic Test	Precise[™] Tumor Molecular Profile Test Precise[™] Liquid Molecular Profile Test	Precise[™] MRD Molecular Residual Disease Monitoring	MyChoice[®] CDx Myriad HRD Companion Diagnostic Test	Prolaris[®] Prostate Cancer Prognostic Test	Foresight[®] Carrier Screen Prequel[®] Prenatal Screen SneakPeek[®]	MyRisk[®] Hereditary Cancer Test BRACAnalysis CDx[®] Germline Companion Diagnostic Test	GeneSight[®] Mental Health Medication Test

>\$30B

of actionable market opportunity

<40%

average market penetration across all categories

<20%

of market share concentrated among Top 3 players

Myriad holds

Top 3 position

in 6 out of 7 active product categories

1: Actionable market indicated against cancers of commercial focus

2: In ovarian, breast, prostate, and pancreatic cancers only

3: Reflective of IHC partnership

Data as of 2022 from third-party global consulting firm and internal estimates

Significant opportunity to accelerate MyRisk growth across Women's Health, Imaging, Oncology and Urology

📖 Roadmap of expected highlights

2024 MyRisk patient portal

MyRisk Medical Management Tool Enhancements


RiskScore studies

Breast Cancer Risk Assessment Program

2025 Panel Expansion | WES (whole exome sequencing)

BRAC CDx to NGS

Figures in thousands



Strong commercial execution driving significant volume growth in the last twelve months

Actionable market size (US only)*	Market penetration*	Market growth**	MYGN market share*
~\$5B	15%	Mid teens	55-60%


Roadmap of expected highlights

2024	Health Economic Outcome Research (HEOR) study*** Significant opportunity to improve payor coverage and ASP
2025	Postpartum Clin Dev Protocol & Study

*Data as of 2022 from third-party global consulting firm and internal Company estimates
**Expected

***This study used data from the Optum Labs Data Warehouse, composed of de-identified administrative claims data for both commercially insured and Medicare Advantage enrollees. The claims data were linked on a de-identified basis with PGx test results.

Figures in thousands



Strong runway for Prolaris with an opportunity to capture more market share with compelling updates

Prolaris®
Prostate Cancer Prognostic Test

Actionable market size (US only)*

~\$600M

Market penetration*

35%

Market growth**

Low teens

MYGN market share*


~40%

Roadmap of expected highlights

2024 Expanded coverage from UnitedHealthcare
ARR (Absolute Risk Reduction) report
Publish 3-yr Metastasis study

2025 Prolaris Post-RP launch

Figures in thousands



*Data as of 2022 from third-party global consulting firm and internal Company estimates

**Expected


A market that continues to grow with potential tailwinds from guideline expansion

Prequel®
Prenatal Screen

Foresight®
Carrier Screen

	Actionable market size (US only)*	Market penetration*	Market growth**	MYGN market share*
PREQUEL	~\$1.3B	45-55%	Low single digits	Low-to-mid teens
FORESIGHT	~\$950M	40-50%	Low single digits	Mid teens

Figures in thousands



Roadmap of expected highlights

2024 Foresight on NovaSeq
Various Prequel studies
Foresight Universal Plus

2025 FirstGene Launch

*Data as of 2022 from third-party global consulting firm and internal Company estimates

**Expected

Pillars of long-term growth and profitability

Science and innovation

Top-tier science delivering products that are clinically validated and demonstrate proven utility (quality, access and cost) in real world clinical settings



Elevated customer experience and commercial execution

Strong digitally enabled commercial platform


Technology enabled operations

Automated, scalable and cost-effective laboratory operations and technology platform

Scalable commercial, lab operations and administrative support services

Advanced regulatory, reimbursement, and revenue cycle capabilities

3-year product roadmap summary of clinical validity/utility and ease of use enhancements



Active expansion of high-quality testing pipeline, addressing real-world community needs



Women's Health

FirstGene™

Multiple Prenatal Screen

Integrated assay for NIPS + carrier screen + fetal recessive status + feto-maternal blood compatibility on a single blood draw on one person.

- Faster turnaround time
- 3x lower cost of goods
- Established reimbursement

Foresight®

Universal Plus panel

Pioneering expanded carrier screen that uses NGS to find pathogenic variants underlying recessive disease.

- Merged couple reporting
- Fully automated lab workflow drives low COGS



Oncology

Precise™ Tumor

Robust tumor profiling & therapy selection

Pan-cancer comprehensive genomic profiling test using Illumina TruSight Oncology 500; may serve as first-line offering.

- Panel size ~2x size (500 genes) of lead competitor; uses both DNA/RNA; ease of use as part of Precise Oncology Solutions
- Established reimbursement path

Precise™ Liquid

Robust tumor profiling & therapy selection

Comprehensive genomic profiling test; may serve as first-line offering or as reflex if solid tumor is insufficient.

- Panel size ~2x size (500 genes) of lead competitor. uses DNA; ease of use as part of Precise Oncology Solutions
- Established reimbursement path

Precise™ MRD

Molecular residual disease monitoring

Monitoring test based on whole genome sequencing to deeply interrogate tumor, detect recurrence earlier and help guide treatment decisions.

- Targets 10x variants
- Known path to reimbursement

* Research Use Only


Transformative prenatal screen running multiple tests at once

Current PROBLEMS with prenatal genetic screening

Providers don't have enough time to talk about genetics




Only **50%** utilization of carrier screening




Only **30%** of fathers get screened when mother is a carrier

Low gross margins on **NIPS** and **ECS**



New SOLUTION

FirstGene™
Multiple Prenatal Screen



- Easier for providers to administer integrated offering
- No need to screen the father
- Estimated 30-40% higher gross margins compared to Foresight or Prequel alone

Key Additions to the Oncology Portfolio, set stage for MRD Launch to follow

Oncology

Precise™ Tumor

Robust tumor profiling & therapy selection

What is It?

Pan-cancer comprehensive genomic profiling test using Illumina TruSight Oncology 500; may serve as first-line offering

Key Advantages

- Panel size ~2x size (500 genes) of lead competitor; uses both DNA/RNA; ease of use as part of Precise Oncology Solutions
- Reimbursed

Precise™ Liquid

Robust tumor profiling & therapy selection

What is It?


Comprehensive genomic profiling test; may serve as first-line offering or as reflex if solid tumor is insufficient

Key Advantages

- Panel size ~2x size (500 genes) of lead competitor; uses DNA; ease of use as part of Precise Oncology Solutions
- LCD Submitted Dec.' 23

Strategic Value of Precise Tumor & Precise Liquid


- A successful Oncology franchise will help medical oncologist select treatments for their patients
- Precise Tumor will complement MyChoice CDx providing physicians with Comprehensive Gene Panel data to inform treatment decision
- Precise Liquid will help physicians who experience solid tumor test failures or do not have adequate tumor samples for testing obtain treatment guidance
- Precise Liquid will offer easier sample collection and sample type synergy with MyRisk and Precise MRD
- Precise Tumor and Precise Liquid will strengthen medical oncology experience to support the Launch of Precise MRD



Precise™ MRD

Molecular Residual Disease Monitoring

Differentiation built upon existing competencies



*patents pending

Higher sensitivity:
detection at 10x
lower tumor levels

100x more of the
genome explored

Over 60x more
targeted sites

Earlier detection
of recurrence


Improving the patient and provider experience




Top 5 Dx test provider requirements

- ✓ Strong clinical validity and utility
- ✓ Comprehensive product offering /menu
- ✓ Fast turnaround times
- ✓ Ease of use in ordering and report utilization
- ✓ Affordability for the patient

Myriad aims to simplify and streamline the genetic screening and testing process. It respects patient privacy, is easy to implement, and provides support at every step.



Enterprise infrastructure: investing for flexibility and scale



Full year and fourth quarter 2023 operating and financial highlights



Full-Year 2023 Revenue Growth Driven by All Three Business Units

+11% YOY

Revenue Growth by Unit:

+15% in Women's Health*

+9% in Pharmacogenomics

+8% in Oncology



Positive Q4'23 Adj. EPS and Adj. Operating Cash Flow

\$0.04 Adj. EPS

reflecting double-digit YOY revenue growth and cost management

\$14 million

Adj. Operating Cash Flow; an increase of \$10 million YOY



Raising 2024 Revenue Guidance: Healthy Balance Sheet

Raising 2024 revenue guidance; introducing positive Adj. EPS guidance

Raised \$118 million net proceeds from equity offering; YE '23 cash & equivalents balance of \$141 million



Ongoing Investments in Strategic Growth Channels

Acquired Precise Tumor and Liquid assets from partner Intermountain Health

Excellent strategic fit; Enables more complete offering to the oncologist

* Excluding SneakPeek, 2023 Women's Health revenue grew 9% YOY

2023 Operational highlights fueling our growth

Team Engagement



86%

Of our team rate Myriad as a “Great Place To Work”



9%

Employee turnover, approximately half of what it was in 2021

Market Perception and Customer Service Levels



70

Net Promoter Score among current Myriad providers ordering across our testing portfolio (2023)



47%

Of genetic counselors surveyed in 2023 had a **more positive impression of Myriad** because of our contributions to ClinVar*

Efficiency & Speed



6.0 days

Rapid turn-around times critical for patients making time-sensitive care decisions



+13%

YOY sales productivity increase with structural optimization, automation and accelerating marketing demand (2023)

Revenue Cycle



+\$45M

Revenue in excess of expectations (2021-2023) with fully enhanced revenue cycle platform



53 Days

Industry leading Days Sales Outstanding (DSO) consistent with Q3 '23

All data as of fourth quarter, 2023, except as otherwise noted


* Brand Equity Research 2023. How does knowing that Myriad Genetics has begun sharing variant data classifications to public database ClinVar affect how you feel about Myriad compared to their competitors?

** Excluding contribution from SneakPeak Early Gender DNA test

Hereditary cancer test, Prenatal and GeneSight volumes continue to drive performance in 2023

Select test volume and growth rates

All figures in thousands, except growth rates



Hereditary cancer testing (HCT) highlights:

- Sixth consecutive quarter of YOY growth in test volumes.
- 10% YOY growth in 4Q '23 HCT volumes in Women's Health.
- 7% YOY growth in 4Q '23 HCT volumes in Oncology.


4Q '23 volume growth by product:

- 8% in Hereditary Cancer
- 17% in Prenatal*
- 21% in Pharmacogenomics
- 4% in Prolaris

* Excluding contributions from the SneakPeek® Early Gender DNA test

2023 financial progression by quarter

All figures in millions, except per share amounts and percentages



*GAAP to non-GAAP reconciliations can be found in the appendix.

Raising 2024 revenue guidance; introducing adjusted EBITDA and EPS

All figures in millions, except per share amounts and percentages

	2024 FINANCIAL GUIDANCE	EXPECTED YEAR-OVER-YEAR CHANGE	2024 COMMENTS
Total revenue	\$820 - \$840	9% - 11%	<p>Raised 2024 revenue guidance range by \$5 million for the full year.</p> <p>Q1 '24 revenue expected to grow at a mid-to-high single digit percentage rate year-over-year; and this growth rate is expected to accelerate throughout the rest of the year.</p>
Gross margin %	69.5% - 70.5%	50 - 150 bps	<p>GM expected to fluctuate in any quarter given product mix, pricing trends and seasonality.</p> <p>Q1 '24 GM expected to reflect typical seasonality, with Q1 '24 margins lower than Q4 '23 gross margins and ramping up throughout rest of 2024.</p>
Adjusted operating expenses*	\$572 - \$582	5% - 7%	
Adjusted EBITDA*	\$20 - \$30		<p>Introducing adjusted EBITDA in the financial guidance table to provide additional insights into the earnings trajectory.</p>
Adjusted EPS*	\$0.00 - \$0.05	+\$0.27 - \$0.32	<p>Q1 '24 adjusted EPS expected to be negative reflecting seasonality.</p>

*The company does not forecast GAAP operating expenses, earnings before interest, tax, depreciation, or amortization (EBITDA), and earnings per share because it cannot predict certain elements that are included in reported GAAP results. See the statement on Non-GAAP Financial Measures at the beginning of this presentation and the Appendix to this presentation for more information about the use of non-GAAP financial measures

Assumes currency rates as of February 27, 2024

Well positioned to take advantage of future market opportunities



Annual revenue growth expected to accelerate to 10%+ in '24-'26

Raised 2024 full-year revenue guidance to \$820 - \$840 million reflecting expected annual growth of 9-11% over 2023



Right to win with core products driving market share gains

Enhanced commercial execution generating double-digit volume growth as adoption rates and competitive position improves



Pipeline addresses large growth markets

Robust and differentiated product pipeline opens access to incremental multi-billion-dollar markets



Operating leverage, profitability, and positive cash flow

Strength of business model, technology platform and enhanced laboratory capabilities expected to drive operating leverage, adjusted profitability and positive adjusted cash flow in 2024-2026



Capital deployment

Disciplined capital deployment; continue to invest in high ROI opportunities within core channels

Q&A